Ulocuplumab
Phase 1Monoclonal antibody
Bristol-Myers SquibbUlocuplumab is one of 72 small molecule programs targeting Macroglobulinemia. It is currently in Phase 1.
2
Indications
3
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Nolvadex
AstraZenecaPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Florbetaben
LLife Molecular Imaging GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Macroglobulinemia1 trial
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Terminated·—·Phase 1·NCT03225716·13 enrolled
Multiple Myeloma1 trial
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
No longer available·—··NCT02666209
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ulocuplumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 1[1]
- Company